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ABSTRACT
Rasagiline is a monoamine oxidase type-B
inhibitor used as monotherapy or in addition
to levodopa in the treatment of Parkinson’s
disease. Once daily administration of rasagiline
makes it easy to use, and allows good
compliance by patients and adherence to
therapy. Several multicenter studies have
noted the effectiveness of rasagiline on both
motor and non-motor symptoms, which
require a complex pharmacologic approach,
such as cognitive disorders. A recent study also
reported a rapid action of rasagiline on motor
symptoms. Positive findings have been
highlighted by an economic model study. This
review analyzes the main studies of rasagiline,
with particular attention to the effectiveness of
the drug on motor symptoms.
Keywords: Monoamine oxidase type-B
inhibitor; Motor symptoms; Neurology;
Parkinson’s disease; Rasagiline
INTRODUCTION
Parkinson’s disease (PD) is a progressive
neurodegenerative disorder characterized by
the selective degeneration of dopaminergic
neurons in the substantia nigra pars compacta
that determines the presence of motor
symptoms, namely bradykinesia, muscle
rigidity, and resting tremor. However, the
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pathology of the disease often becomes
complicated by the presence of non-motor
symptoms, which require complex drug
treatment, including autonomic disorders,
postural instability, bowel and bladder
dysfunction, mental disorders (anxiety,
apathy, dementia, depression, psychosis), pain,
and sleep disorders (daily hypersomnolence,
nocturnal akinesia, restless legs syndrome).
The majority of drug therapies used in PD aim
at increasing the level of striatal dopamine. This
can be achieved by administering levodopa,
directly stimulating post-synaptic dopamine
receptors with dopamine agonists (DA).
Another therapeutic strategy involves
inhibiting the enzymes responsible for
degrading levodopa [1, 2].
The enzyme monoamine oxidase (MAO) is a
protein of the outer mitochondrial membrane
that metabolizes neurotransmitters in the brain
and in other tissues. Its inhibition can
potentially elevate levels of the major
metabolites of neurotransmitters such as
dopamine and tyramine [3]. MAO is classified
as MAO-A and MAO-B: MAO-A is found mostly
in the intestinal tract but also in some
presynaptic neurons in the brain, while MAO-
B is predominant in the brain, mainly localized
in glial cells near the dopaminergic synapses,
and regulates both the releasable stores and free
levels of free intra-neuronal dopamine [4, 5].
Rasagiline is a selective and irreversible
inhibitor of MAO-B, which can be used either
as monotherapy or as adjunctive therapy to
levodopa or to DA agents in PD [6]. It is five
times more potent than selegiline in inhibiting
the activity of MAO-B after repeated
administration [7]. In healthy volunteers who
received a single oral dose of 1, 2, 5, or 10 mg
rasagiline, maximum inhibition of MAO-B
platelet activity, considered to be a marker of
brain MAO-B, was observed 1 h after
administration [8]. Significant intergroup
differences in MAO-B platelet inhibition
favoring rasagiline 2, 5, and 10 mg/day were
evident 2 h after the first dose, while multiple
doses of rasagiline 2 mg per day showed [99%
MAO-B inhibition by day 6 [8]. For all multiple
doses of rasagiline, maximum inhibition of
MAO-B platelet activity was maintained up to
24 h after the last administration, and activity
returned to baseline levels 2 weeks after the
cessation of therapy. In patients with PD, MAO-
B platelet activity was completely inhibited
following 7 days treatment with 0.5, 1, or
2 mg/day rasagiline [9].
This article reviews the main pharmacologic,
pharmacodynamic, and pharmacokinetic
properties of rasagiline in the treatment of PD.
MATERIALS AND METHODS
We identified pertinent studies by searching
Medline-Pubmed databases (1992–2013) using
the key words: rasagiline, MAO-B inhibitors,
and Parkinson’s disease. We included articles
reporting on double-blind, placebo-controlled,
randomized studies, open-label randomized
studies, controlled studies, and pharmacologic
studies. We also considered review articles and
research support studies. Articles selected for
the review specifically described results of
randomized double-blind clinical studies, and
long-term clinical trials.
The authors independently selected results
focusing on the final outcome measurements,
different scales used on clinical or
pharmacologic efficacy, statistical significance,
and adverse events. Each article was
independently reviewed by authors indicating
the major interesting data in the field of
effectiveness and safety, and disagreements
were solved by discussion.
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We also followed the indications of the
PRISMA statement: multicenter double-blind,
placebo-controlled parallel group, delayed start/
clinical trial, double-blind trial, post hoc
analysis, open-label extension, post-marketing
observational open-label studies [10].
TEMPO Study
The TEMPO study was a multicenter,
randomized, double-blind placebo-controlled
study of rasagiline in 404 patients with early-
stage PD [11]. Patients were randomized to
receive rasagiline at a dose of 1 or 2 mg/day or
placebo. An initial titration period of 1 week
was followed by a maintenance period of
25 weeks. The primary measure of efficacy was
the change in total Unified Parkinson’s Disease
Rating Scale (UPDRS) score [12] between
baseline and 26 weeks of treatment.
Secondary end points were: cognitive
deficits; difficulties with activities of daily
living (ADL) [13, 14]; evaluation of motor
subscales of the UPDRS, as well as subscores
based on symptoms (tremor, rigidity,
bradykinesia, instability/gait, and postural
changes) [15]. Other secondary variables
included changes to the scale of Hoehn and
Yahr (H&Y) [16], the Schwab and England ADL
scale [17], the Beck Depression Inventory score
[18], the Mini Mental State Examination
(MMSE) score [19], timed motor test scores
[20], and quality of life (QoL) on the PD
Quality of Life (PDQUALIF) scale [21].
Patients who experienced a worsening of
scores,\3 units in their total UPDRS score from
baseline to 26 weeks were classified as
responders.
Calculation of the Power of the Study
According to the Bonferroni method [22], 120
patients per group (360 in total) were required
to give a power of between 81% and 93% to
detect a significant effect of one or both dosages
of rasagiline, when treatment with 2 mg/day
rasagiline resulted in an improvement of 3
points in UPDRS scores compared with
placebo, and treatment with 1 mg/day
rasagiline resulted in an improvement in
UPDRS scores of between 0 and 3 units.
Results
Mean [standard deviation (SD)] UPDRS scores at
26 weeks were 24.8 (12.3) in the rasagiline
1 mg/day group, 26.6 (11.8) in the rasagiline
2 mg/day group, and 28.4 (14.3) in the placebo
group [11]. The unadjusted changes from
baseline were: 0.1 (6.8), 0.7 (5.8), and 3.9 (7.5)
in the rasagiline 1 mg/day, 2 mg/day, and
placebo groups, respectively. Both active
treatment groups showed benefits compared
with the placebo group (P\0.001 for each
comparison).
The analysis of responders who showed a
change in UPDRS total score \3 units also
demonstrated the effects of each active
treatment (placebo, 49%; rasagiline 1 mg/day,
66%, and rasagiline 2 mg/day, 67%, with
P = 0.004 and P = 0.001 for the 1 and 2 mg
rasagiline group vs. placebo, respectively). Of
138 patients in the placebo group, 23 (16.7%)
reached the secondary end point of needing
levodopa therapy, compared with 15/134
patients (11.2%) and 22/132 patients (16.7%)
receiving 1 and 2 mg/day rasagiline,
respectively [11].
The Kaplan–Meier analysis showed no
statistically significant differences in the start
of adjunctive therapy among the three
treatment groups. Both groups treated with
rasagiline showed significant improvement in
PDQUALIF scores compared with placebo. The
exploratory analysis suggested that the benefit
occurred mainly in the measurement of
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self-image/sexuality subscales, with negligible
effects on the social role subscale. Significant
benefits were noted in responses to one
question comparing present PD symptoms
with those experienced 3 months earlier [11].
Adverse events (AEs) were no more frequent
in the active treatment groups than in the
placebo group. The most commonly observed
AEs were infection (16%) and headache (12%).
Other AEs occurred with a frequency of \10%.
There were no statistically significant
differences in the rates of early termination
between the treatment groups and the placebo
group [11]. Twenty serious AEs (defined as
hospitalizations or new malignancies) occurred
during the study: four in the placebo group, six
in the 1 mg/day rasagiline group, and ten in the
2 mg/day rasagiline group [11]. One patient in
the 2 mg/day rasagiline group experienced two
serious AEs (hospitalization for depression and
delirium).
PRESTO Study
The PRESTO study was a multicenter,
randomized, placebo-controlled double-blind
phase III study in 472 patients with PD who
experienced at least 2.5 h of being ‘off’ (poor
motor function) every day despite optimized
treatment with levodopa [23].
Patients were randomized to receive
rasagiline at a dose of 1 or 0.5 mg/day, or
placebo. Eligible patients were aged [30 years
with idiopathic PD and were in a modified HY
stage of\5 in the ‘off’ state. Patients monitored
their blood pressure before and after the main
meal of the day for 7 days before the baseline,
and week 3, and week 26 visits.
The primary efficacy end point was the
change from baseline in mean total daily ‘off’
time measured through patient diaries, and the
average was considered during the treatment
period (from week 6, 14, and 26). The secondary
end point was the investigator’s clinical global
impression of improvement, measured on a
global scale that included 7 points ranging
from ‘significantly improved’ to ‘no change’ to
‘significantly worsened’., as well as changes
from baseline in the UPDRS-ADL scale, and
quality of life as measured by the PDQUALIF
scale. Additional end points were: changes from
baseline in the total average daily ‘on’ and ‘off’
times on the Schwab and England ADL scale,
and in ‘on’ times on the UPDRS-ADL scale.
The primary statistical analysis included data
from all randomized patients provided with the
diary (n = 451). To evaluate the effect of
patients who withdrew, the analyses were
repeated using only patients who completed
the study (n = 414) and patients who completed
all procedures according to the protocol
(n = 359). The measures of secondary end
points were made in the same way as the
primary end point. The most common
deviations were related to early termination
(12%), less than six acceptable daily diaries
(10%, mainly in patients who left the study
prematurely), and change in daily levodopa or
other anti-PD dosage by [20% from baseline
during the last 20 weeks of the study (4%) [23].
Compliance to treatment was high, as
demonstrated by counting pills, with 95% of
patients treated with at least 90% of the
planned doses. Between baseline and week 26,
patients treated with placebo decreased their
mean ± SD daily dosage of levodopa from
12 ± 142 mg, while patients treated with
0.5 mg/day rasagiline decreased their dosages
by 32 ± 122 mg, and patients treated with 1 mg
per rasagiline decreased administration of
levodopa by approximately 36 ± 133 mg. The
majority of patients were taking other anti-
parkinsonian drugs, including DA, entacapone,
and amantadine [23].
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Results
During the treatment period, the average total
daily ‘off’ time decreased from baseline by
1.85 h (29%) in patients treated with 1 mg/day
per day rasagiline, 1.41 h (23%) with 0.5 mg/
day rasagiline, and 0.91 h (15%) with placebo.
Patients treated with 1 mg/day rasagiline had
0.94 h [95% confidence interval (CI) 0.51–1.36,
P\0.001] less ‘off’ time a day compared with
placebo. Patients treated with 0.5 mg/day
rasagiline had 0.49 h (95% CI 0.08–0.91,
P = 0.02) less ‘off’ time compared with
placebo. The differences compared to baseline
between the groups were maintained
throughout the treatment period. There was
no difference in treatment effects between the
study centers (P = 0.58). Compared with
placebo, the clinical global impression,
UPDRS-ADL score during ‘off’ time, and
UPDRS-motor score during ‘on’ time improved
significantly during treatment with rasagiline
[23].
Quality of life, as measured by the
PDQUALIF score, showed a trend toward
improvement in patients treated with 0.5 mg/
day rasagiline (P = 0.07), but not with 1 mg/day
rasagiline. The social subscale of the PDQUALIF
scale showed a benefit for both rasagiline doses
compared with placebo, the outlook subscale
showed a benefit for the 0.5 mg/day dose, while
the function, image, independence, sleep, and
urinary subscales showed no difference
compared with placebo. Exploratory analyses
showed a significant increase in the amount of
time ‘on’ with both doses of rasagiline,
corresponding to reductions in the overall
time ‘off’. In the group treated with 0.5 mg/
day rasagiline, there was a greater period of time
without troublesome dyskinesia. In the group
treated with rasagiline 1 mg/day, 32% of the
increase in ‘on’ time included the presence of
troublesome dyskinesias. The rasagiline 1 mg/
day group showed a significant improvement in
the Schwab and England ADL scale during ‘off’
times (P = 0.02), but a dose of 0.5 mg/day did
not produce the same result. The post hoc
analysis of UPDRS subscores during the time
‘on’ showed a significant improvement in
rigidity, bradykinesia, and tremor in patients
treated with 1 mg/day rasagiline, and in
postural instability and in gait and tremor in
patients treated with the 0.5 mg/day dose [23].
Adverse events were reported in 87% of
patients treated with placebo, 91% receiving
0.5 mg/day rasagiline, and 95% receiving 1 mg/
day rasagiline.
These tended to be gastrointestinal AEs and
appeared to be dose related. Dyskinesias were
reported as an AE in 10% of placebo-treated
patients, and in 18% of patients treated with
either dose of rasagiline (P = 0.03 for combined
rasagiline groups vs. placebo). Balance
difficulties occurred more often in patients
treated with rasagiline, but they did not
appear to be dose related. Depression was
significantly less common in patients treated
with 0.5 mg rasagiline compared with placebo
(P = 0.04).
There were 22 serious AEs in 14 patients
treated with placebo, 42 in 21 patients treated
with 0.5 mg rasagiline, and 27 in 18 patients
treated with 1 mg rasagiline.
The most common serious AEs were related
to accidental injury (n = 6), arthritis, worsening
PD, melanoma, stroke (n = 3), and urinary tract
infections (n = 3), and none was significantly
more common in patients treated with
rasagiline than with placebo.
Rasagiline did not have negative effects on
blood pressure or heart rate. During treatment,
dermatologic examinations revealed three
patients with melanoma (1 in the 0.5 mg
rasagiline group and 2 patients in the 1 mg
rasagiline group). One additional patient was
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identified as having a melanoma before starting
the study [23].
LARGO Study
The LARGO study was a randomized, double-
blind, multicenter 18-week phase III trial of
rasagiline in levodopa-treated patients with PD
and motor fluctuations [24]. In total, 687
outpatients were randomly assigned to receive
oral rasagiline 1 mg/day (n = 231), entacapone
200 mg with every levodopa dose (n = 227)), or
placebo (n = 229). As a comparator, this trial
also included an adjunct entacapone [25–28].
The primary outcome measure was change in
total daily ‘off’ time. The secondary outcome
measures included the clinical global
improvement (CGI) score [29] and the UPDRS
scores. A post hoc analysis of the primary and
secondary efficacy variables was undertaken to
assess treatment effects stratified by age ([70 or
\70 years) and according to whether patients
received concomitant treatment with DA.
Additional exploratory end points included:
responder analysis, mean change from baseline
in the ‘on’ state with or without troublesome
dyskinesia, and UPDRS-dyskinesia.
Results
There were no major differences between study
groups. Dopamine agonists were the most
common class of concomitant drugs for PD
(about 60%, i.e., 130–141 patients in each
group). Amantadine and anticholinergic drugs
were the other most frequently used therapies
with rasagiline. Rasagiline reduced the mean
total daily ‘off’ time from baseline (primary end
point) by more than 1 h, almost three times
more than the reduction with placebo
(P = 0.0001) and increased daily ‘on’ time
without troublesome dyskinesia (0.85 h vs.
placebo 0.03 h; P = 0.0005). This effect was
already evident at the first efficacy assessment
(week 6, adjusted mean change -1.31 vs. -0.27
for placebo; P = 0.0001). Additionally, patients’
diaries revealed an accompanying increase in
daily ‘on’ time with the active treatments, most
of which was without troublesome dyskinesia.
No change in the duration of ‘on’ time with
troublesome dyskinesia was recorded.
Responder analysis also supported these
findings. This improvement in drug efficacy
was accompanied by a small, but significant
reduction in levodopa dose with rasagiline
(-24 mg/day) compared with a 5 mg/day
increase with placebo (P = 0.0003 vs. placebo).
At week 18, the clinical global improvement
score improved compared with placebo by 0.49
units for rasagiline (P = 0.0001). The two
UPDRS secondary end points were significantly
improved by rasagiline and entacapone:
UPDRS-motor (‘on’ state) and UPDRS-ADL
(‘off’ state). The three UPDRS exploratory
subscores measuring dopa-responsive
symptoms (tremor, rigidity, and bradykinesia)
also significantly improved on rasagiline.
UPDRS-dyskinesia scores showed no significant
increase when patients were receiving either
active treatment compared with placebo.
Three other UPDRS subscores were
significantly improved by rasagiline, but not
by entacapone: UPDRS-PIGD, UPDRS-freezing
(in patients who, at baseline, experienced
freezing when walking), and UPDRS-motor in
the practically defined ‘off’ state.
Results of primary efficacy analysis were
similar in both active treatment groups in old
([70 years) and young (\70 years) patients. For
patients receiving rasagiline, the difference
versus that of placebo was -0.79 h in the
young group, and -0.76 h in the old group,
indicating similarity between the strata
(P = 0.961). Significant mean improvements in
CGI scores were recorded (-0.86 rasagiline;
46 Neurol Ther (2014) 3:41–66
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P = 0.0001). Changes in UPDRS-ADL scores also
significantly improved during ‘off’ time (-1.71
vs. placebo; P = 0.0001) and motor function
during ‘on’ time (-2.94 vs. placebo;
P = 0.0001).
Rasagiline was well tolerated with a safety
profile similar to that of placebo. Importantly,
the drug was equally well tolerated in the old-
age group (C70 years) with no evidence of
increased hallucinations, a common concern
with DA. No side effects of dopaminergic
treatment were recorded, such as abnormal
daytime somnolence, nausea, or leg edema.
Further, rasagiline was given simply, once
daily, without titration, both relevant factors
for patients who might already be receiving
complicated treatment regimens, including the
slow titration needed with DA.
Post hoc Analyses of the PRESTO
and LARGO Trials
Post hoc analyses assessed clinical effects of
rasagiline 1 mg/day on cardinal PD symptoms
and motor fluctuations in defined patient
subgroups using pooled data from PRESTO and
LARGO [30]. The effects of rasagiline were
measured on individual cardinal PD symptoms
during ‘on’ time and mean change from
baseline in daily ‘off’ time in subgroups of
patients who at baseline were receiving only
levodopa, were considered ‘mild fluctuators’
(daily ‘off’ time B4 h), and who were or were
not receiving concomitant DA or catechol-O-
methyltransferase inhibitor (COMT-I) therapy.
The consistency between PRESTO and
LARGO study designs and outcomes allow data
pooling [31]. In both studies, patients could
receive stable doses of other dopaminergic
medications in addition to levodopa and the
study drug. The primary efficacy variable was
adjusted mean change from baseline in daily
‘off’ time, measured by patients in 24-h diaries
every 30 min for 3 days before beginning study
treatment and prior to site visits on weeks 6, 14,
and 26 in PRESTO and weeks 6, 10, 14, and 18
in LARGO. Patients rated their status as ‘on with
troublesome dyskinesia, ‘on without dyskinesia
or without troublesome dyskinesia’, ‘off,’ or
‘asleep’. Secondary end points included changes
from baseline in the UPDRS scale and ADL
subscale score during ‘off’ time and changes in
the UPDRS-motor subscale score during ‘on’
time. PRESTO and LARGO data were pooled to
evaluate the primary and secondary end points
in all patients, and in the subgroup of patients
who were receiving only levodopa at baseline
[32]. Pooled data were also used to evaluate the
effect of rasagiline on cardinal symptoms of PD
during ‘on’ time [33] and included analysis of
bradykinesia, rigidity, tremor, postural stability,
and gait, using the intent-to-treat (ITT)
principle.
Results
When added to already optimized
dopaminergic treatment, rasagiline 1 mg/day
reduced adjusted mean total daily ‘off’ time by
-0.85 h (95% CI -1.16 to -0.55, P\0.0001)
compared with placebo. Similarly, compared
with placebo, rasagiline 1 mg/day significantly
improved mean total daily ‘on’ time without
dyskinesia or with non-troublesome dyskinesia
(0.73 h, 95% CI 0.37–1.08), UPDRS-ADL ‘off’
score (-1.56 points, 95% CI -2.18 to -0.94),
and UPDRS-motor ‘on’ score (-2.87 points,
95% CI -3.94 to -1.79); P\0.0001 for all
comparisons. When added to existing
dopaminergic treatment, rasagiline 1 mg/day
significantly improved all cardinal motor
symptoms of PD compared with placebo
during ‘on’ time (P\0.05), with treatment
effects ranging from -0.09 for postural
stability to -1.22 for bradykinesia. In addition,
Neurol Ther (2014) 3:41–66 47
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rasagiline significantly reduced mean ‘off’ time
by -1.44 h (0.20), compared with -0.66 h
(0.19) with placebo (treatment effect -0.78 h;
P\0.01). Similarly, the treatment effect of
rasagiline relative to placebo was statistically
significant for all secondary end points: -3.74
(0.76) versus -0.17 (0.71), respectively, for
baseline UPDRS-motor ‘on’ scores (treatment
effect -3.57, P\0.001), and -2.25 (0.44) and
-0.59 (0.42), respectively, for baseline mean
UPDRS-ADL ‘off’ scores (treatment effect -1.66,
P\0.01). The addition of rasagiline to levodopa
and potentially other dopaminergic treatments
significantly reduced ‘off’ time by 0.76 h
compared with a 0.22 h increase with placebo
(treatment effect -0.98 h; P\0.001). Rasagiline
1 mg/day significantly reduced daily ‘off’ time
versus placebo in patients receiving
concomitant DA (-0.92 h, P\0.0001) and
those not (-0.72 h, P\0.0066). There was no
significant difference between effect sizes of
rasagiline-related reductions in daily ‘off’ time
between patients receiving concomitant DA or
not (P = 0.5506). Similarly, rasagiline 1 mg/day
significantly improved all secondary end points
in both patients receiving concomitant DA and
those not receiving concomitant DA.
Summary
Post hoc analyses of the PRESTO and LARGO
trials showed that rasagiline is a good choice as
first adjunct therapy in levodopa-treated
patients; rasagiline benefits patients with
relatively minor motor symptoms suggestive of
early ‘wearing off’. The well-established benefits
of rasagiline on motor function are related to
improvement of all of the cardinal symptoms of
PD, and rasagiline added to combination
therapy with levodopa and DA or levodopa
and COMT-I is well tolerated and further
improves symptoms in patients with PD
experiencing motor fluctuations. Therefore,
adding rasagiline to an already optimized
dopaminergic treatment regimen in patients
with relatively mild motor fluctuations (B4 h/
day at study entry) can reduce mean total daily
‘off’ time by approximately 25%, whereas total
daily ‘off’ time in placebo-treated patients
increased by approximately 7% during the
double-blind studies (P\0.01 vs. placebo).
ADAGIO Study
The ADAGIO study was a double-blind, placebo-
controlled, delayed-start study, which
randomized 1,176 patients with PD at an early
stage and not requiring dopimanergic therapy,
to receive rasagiline 1 or 2 mg/day for 72 weeks
(early-start group) or placebo for 36 weeks
followed by rasagiline 1 or 2 mg/day for
another 36 weeks (delayed-start group) [34].
The delayed-start design was used to examine
the potential neuroprotective effects of
rasagiline in PD. Patients assigned to placebo
in phase I who required anti-parkinsonian
therapy were included automatically in the
active treatment phase (early converters).
The primary analysis of the study included
three end points based on the change from
baseline in UPDRS scores in the rasagiline versus
placebo groups: between the 12th and 32nd
week of active treatment; between the 1st and
72nd week of active treatment; and between the
48th and 72nd week of active treatment. The
secondary end point of the study was to
compare and estimate the changes to UPDRS
score at baseline and at the 72nd week in
patients treated with rasagiline 1 mg and
2 mg/day.
Results
Overall 1,164 patients were included in the first
primary end point analysis, and 996 (85%) were
included in the analyses of the second and third
48 Neurol Ther (2014) 3:41–66
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primary end points. There were no significant
differences among the treatment groups at
baseline. The mean disease duration from the
time of diagnosis was 4.5 months, and the mean
total score of 20.4 was obtained on the UPDRS.
Patients treated with rasagiline 1 mg/day
demonstrated a progression of disease, as
measured by UPDRS, lower than in patients
treated with placebo from week 12 to 36
(0.09 ± 0.02 points per week vs. 0.14 ± 0.01
points per week; P = 0.01). In patients receiving
rasagiline 1 mg/day, early-start progression was
observed at lower average total UPDRS scores
between baseline and week 72 compared with
the delayed-start group (2.82 ± 0.53 points per
week vs. 4.50 ± 0.56 points per week; P = 0.02).
The estimates of the slope of the UPDRS
between week 48 and week 72, at a dose of
rasagiline 1 mg/day, showed non-inferiority of
the response of the score between the early-start
group and the delayed-start group (0.085 ± 0.02
points per week vs. 0.085 ± 0.02 points per
week; P\0.001). Rasagiline at a dose of 1 mg/
day achieved all three primary end points of the
study. For patients who received rasagiline
1 mg/day from baseline to the end of phase I,
the effectiveness of treatment was superior to
placebo (1.26 ± 0.36 points per week of UPDRS
vs. 4.27 ± 0.26 points per week; P\0.001). For
patients who were treated with rasagiline 2 mg/
day, a lower progression of disease was observed
compared with placebo between week 12 and
week 36 on the UPDRS (0.07 ± 0.02 points per
week vs. 0.014 ± 0.01; P\0.001). Among
patients treated with rasagiline 2 mg/day, no
significant difference in the overall UPDRS score
between baseline and week 72 was noted in
patients treated early (3.47 ± 0.50 points per
week vs. 3.11 ± 0.50 points per week for the
delayed-start group; P = 0.60). The estimates of
the slope of the UPDRS between week 48 and
week 72, at a dose of 2 mg/day rasagiline,
showed non-inferiority of the response
between early-start patients and delayed-start
patients (0.094 ± 0.01 points per week vs.
0.065 ± 0.02 points per week; P\0.001). The
estimated secondary end point for rasagiline
2 mg daily was superior to placebo (1.11 ± 0.36
points per week vs. 4.27 ± 0.26 points per week;
P\0.001). Rasagiline at a dosage of 2 mg/day
did not reach the three primary end points of
the study [34].
Post hoc Analysis
In considering the possibility that the effect of
disease modification with rasagiline 2 mg/day
may be masked by a mild disease state, the
primary and secondary analyses were performed
in patients with a UPDRS score[25.5 at baseline
[34]. Among patients treated with 2 mg/day
rasagiline, the difference in the UPDRS scores
from baseline to week 72 of the early-start group
and the delayed-start group was significantly
higher among patients with baseline UPDRS
scores in the highest than among patients with
scores in the other three quartiles (P = 0.03).
Therefore, patients in these subgroups can be
considered separately. The patients who
received 1 or 2 mg/day rasagiline, and who
had a baseline score that fell in the highest
quartile, met both the primary end point and
the secondary end point. The 114 patients who
had a UPDRS score in the highest quartile, and
who received a dose of 2 mg/day rasagiline in
the early-start treatment group, had less
progression in overall UPDRS scores between
baseline and week 72 (-3.63 ± 1.72 points;
P = 0.04). In the 105 patients who had a
highest quartile UPDRS score and who
received a dose of 1 mg/day rasagiline in early-
start treatment group, had less progression in
overall UPDRS scores from baseline to week 72
(-3.40 ± 1.66 points; P = 0.04). Patients with
UPDRS scores within the lower quartile (\25.5)
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at baseline did not meet the primary end points
[34].
Safety
There were no significant differences in AEs
among the study groups, which were: falls, back
pain, nasopharyngitis, arthralgia, headache,
musculoskeletal pain, nausea or vomiting,
hypertension, orthostatic hypotension,
somnolence, and hallucination. One patient in
the early-start group who received rasagiline at a
dose of 1 mg/day had a melanoma at week 72.
No patient had tyramine or serotonin reactions
[34].
Summary
Early treatment with rasagiline at a dose of
1 mg/day provided benefits that were consistent
with a possible neuroprotective effect, but early
treatment with rasagiline at a dose of 2 mg/day
did not. Both doses had beneficial effects on
symptoms, as compared to placebo, findings
that are similar to those that have been reported
previously. Because the two doses were
associated with different outcomes, the study
results must be interpreted with caution.
Long-Term Outcome of Early Versus
Delayed Rasagiline Treatment in Early
Parkinson’s Disease
Hauser and colleagues [35] designed a study to
evaluate the results of the long-term open-label
extension of the TEMPO study. Patients were
treated with rasagiline for a maximum of
6.5 years. The objective of the study was to
compare progression of long-term illness,
assessed by the overall UPDRS score, in
patients treated early with rasagiline compared
with patients who received it later.
Patients in the TEMPO study (n = 404) were
randomly assigned to initial treatment with
rasagiline (early-start group) or placebo for
6 months followed by rasagiline (delayed-onset
group). Those who chose to participate in the
open-label extension study (n = 306) continued
to receive rasagiline as well as other drugs for
PD, if necessary. The average duration of the
study was 3.6 ± 2.1 years; 177 patients took
rasagiline for [5 years. During the entire
6.5 years of follow-up, the adjusted mean
difference in change from baseline in total
UPDRS score was 2.5 units [standard error (SE)
1.1; P = 0.021] or 16% (SE 5.7; P = 0.006) for
early treatment compared with delayed
treatment. The values obtained in the early-
start group were better than in the delayed-start
group at all time points. Patients who
completed the 52-week double-blind TEMPO
study were enrolled into the open-label
extension study. Investigators and patients
were still blinded to treatment. Patients were
enrolled in the TEMPO from November 1997 to
June 1999. The results reported here are based
on a database reporting the open-label
extension until June 2004. Follow-up was
16.5 years estimated from the beginning of the
TEMPO study database, but the time of active
enrollment in the study for patients ranged
according to functional specific start times and
possible discontinuation of treatment. During
the open-label extension, all patients were
initially treated with rasagiline 2 mg/day.
Dosage was changed to 1 mg/day in 2000 in
line with the TEMPO study.
Results
Of the 404 patients enrolled in the TEMPO
study, 266 were randomly assigned to initial
treatment with rasagiline 1 or 2 mg, and 138
were randomly assigned to treatment with
placebo (delayed-start rasagiline). The
treatment groups were comparable with respect
to age, sex, and characteristics of PD. A total of
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360 patients who completed the double-blind
phase of the TEMPO study were enrolled, and
306 patients chose to participate in the open-
label extension. The average duration of the
study for patients in the ITT group was 3.6, 6.0,
and 2.1 years for the 1 mg, 2 mg, and placebo
groups, respectively, and did not differ between
the groups. The average duration of the study
was 3.5, 6.0, and 2.2 years, respectively, in the
group with early initiation, and 3.6, 6.0, and
2.1 years, respectively in the group with delayed
onset; 177 patients continued to receive
rasagiline at the time of database lock.
Efficacy
Changes from baseline to the last visit in the
TEMPO study were assessed using the UPDRS
score. For the entire period of observation
lasting 6.5 years, the adjusted mean difference
in change from baseline, expressed as total
UPDRS score, was 2.5 units (SE 1.1) (P = 0.021)
in favor of early-onset group compared to
treatment with rasagiline in early delayed.
This corresponds to a relative difference in
mean percentage change from baseline
between groups of 16% (SE 5.7, P = 0.006).
Although the correlation between treatment
and time was significant for both analyses
(P = 0.0146 for changing UPDRS score and
P = 0.0126 for the percentage changes of
UPDRS score), the value for the early
treatment group was numerically better than
delayed onset of treatment in all the scores and
this correlation reflects the observed variability
in the differences between the group that
started treatment early and late-start group
including a decrease in differences after 1 year
compared to 6 months of therapy and an
increase in the difference between the groups
after 4 years.
The analysis evaluated at intervals of
6 months revealed less significant
deterioration, expressed as a percentage of
change in total UPDRS score, in the early-start
group at 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years
(P\0.05). Changes in the UPDRS-ADL motor
score were better in the early-start group, with
mean differences expressed as a percentage of
change from baseline between the groups of
11.9% (SE 5.9, P = 0.046) and 39.1% (SE 17.7,
P = 0.028), respectively.
Of the 177 patients who remained in the
study until the opening of the database, 114
were part of the group treated since the very
start of the study, and 63 were part of the group
with delayed onset, consistent with the ratio of
the original randomization. The average
duration of treatment with rasagiline was
5.6 ± 0.4 years for the group at the beginning
of treatment and 5.5 ± 0.4 years for the delayed
start. The baseline characteristics of the patients
who remained in the study until the end of the
opening of the database, compared with the ITT
population, had longer time from diagnosis to
PD and slightly lower than the average total
UPDRS score and HY classification. For these
177 patients, the adjusted mean difference in
total UPDRS score was 2.42 units (SE ± 1.04,
P = 0.0218) in favor of the early-start group,
corresponding to an average relative difference
in change percentage from baseline of 17%
(SE ± 5.4, P = 0.002).
Other Dopaminergic Drugs
The average length of time from baseline to
study time to adding an additional
dopaminergic treatment was similar for the
early-start group and the delayed-start group
(respectively 1.5 years and 1.8 years). Similarly,
the percentage of patients who started levodopa
or a further additional dopaminergic therapy
was comparable for both the early treatment
group and for the delayed treatment group.
Similarly, the equivalent dosage of levodopa did
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not differ significantly in all 6-monthly
intervals between the groups.
Motor Complications
For the 211 patients for whom data on
fluctuations and dyskinesias were collected,
the average time period (estimated with the
Kaplan–Meier estimates) of the appearance of
fluctuations was 6.1 years in the group with
early onset (n = 75) and 6.0 years in the group
with delayed onset (n = 136). It was not possible
to evaluate the average time period for the
appearance of dyskinesias, but the time period
for 25% of the patients being tested was
comparable between the two groups: 5.2
compared with 5.9 years. The appearance of
the first fluctuations or dyskinesias was 5.5 years
in both groups at the beginning and in the early
to late start. There were no significant
differences using the log-rank test. All patients
who reported the appearance of dyskinesias in
therapy with rasagiline were previously treated
with levodopa and most (75.5%) were also
treated with a DA. Similarly, all fluctuating
patients were treated with levodopa (16.9%), a
DA (15.7%), or both (67.4%).
Long-Term Efficacy of Rasagiline in Early
Parkinson’s Disease
Lew et al. [36] conducted a multicenter, double-
blind, placebo-controlled, parallel group
delayed-start trial to evaluate the long-term
efficacy, safety, and tolerability of treatment
with rasagiline monotherapy in patients with
PD undergoing treatment for a period of
12 months in the TEMPO trial. Patients were
followed for up to 6.5 years with an average of
3.5 ± 2.1 years. After the first 12 months, other
drugs for PD were added depending on the case.
Of the patients who were still in the trial after
2 years, 46% were kept on monotherapy with
rasagiline. Most of the patients received a DA
before administration of levodopa as the first
additional DA.
In the initial cohort TEMPO study (who had
enrolled 398 patients), 360 patients completed
the double-blind phase and 306 (85%)
participated in the open-label phase. During
the first 12 months, enrolled subjects receiving
placebo, or 1 mg or 2 mg per day of rasagiline.
During the open-label phase all subjects were
administered 2 mg of rasagiline once daily.
The dose of rasagiline was changed to 1 mg/
day after 6 months if the efficacy data did not
show any difference between the two doses (1 or
2 mg/day). The average duration of treatment
with 1 mg/day was 34.1 ± 17.4 months (range
5–65 days, 9 months), while the average
duration with 2 mg/day was 15.8 ± 8.3 months.
During the open-label phase, patients were
visited approximately every 3 months. UPDRS
Parts I to III (‘on’), and HY stage were performed.
At each visit, the investigator reported the
presence of spontaneous AEs and evaluated the
possible need for additional therapy.
Results
The average annual rate of progression assessed
by the UPDRS for all patients was equal to 1.93
units (interquartile range 4.99 units). Using the
Kaplan–Meier analysis the average time
required in the first stage to reach the stage III
of H&Y has not been reached, but the time the
25th percentile required to reach the stage III to
the stairs of H&Y was 5.4 years. The percentage
of patients on monotherapy with rasagiline at
2 years was 42% (95% CI 36.2–46.9). At 2 years,
the remaining 46% of the cohort had received
rasagiline monotherapy.
Baseline UPDRS scores in patients treated
with rasagiline monotherapy for 2 years
(n = 121) differed significantly compared with
patients requiring additional dopaminergic
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therapy (n = 145). Patients on monotherapy
were older than those needing additional
dopaminergic therapy (average age: 62.3 vs.
59.1 years, P = 0.01), had a lower score of
disease initiation of treatment with rasagiline
(mean UPDRS total 20.0 vs. 28.1 units,
P\0.0001), and had a lower UPDRS-motor
score (14.1 vs. 19.4, P = 0.0001), although the
same time had elapsed from diagnosis (1.1 vs.
1.3 years, P[0.05).
At 4 years, 22.5% of patients were
maintained with rasagiline monotherapy, and
by 6–6.5 years only 13.0% remained on
monotherapy. At 4 years, approximately one-
third of patients were treated with rasagiline
plus a DA. The percentage of patients treated
with rasagiline plus levodopa was gradually
increased (from 10.9% at 2 years to 17.4% at
6 years). By 6 years, 60.9% of patients were on
triple therapy with rasagiline, levodopa, and
DA.
Efficacy and Tolerability of Rasagiline in
Daily Clinical Use: Post-Marketing
Observational Study in Patients with
Parkinson’s Disease
Reichmann et al. conducted a post-marketing
observational study that investigated the
efficacy and tolerability of rasagiline in daily
clinical practice in Germany [37]. It also
examined the subjective assessment of quality
of life after treatment with rasagiline. The study
included patients with idiopathic PD who
received rasagiline (the recommended dose of
1 mg/day) as monotherapy or in combination
therapy. The treatment and observation period
was approximately 4 months.
Outcome Measures
Outcome measures, including the change from
baseline, were assessed on the Columbia
University Rating Scale (CURS) [38], the
UPDRS subscale for fluctuation and daily ‘off’
time (daily diaries of patients) [12], and the PD
Questionnaire-39 (PDQ-39) [39]. Adverse drug
reactions (ADRs) and AEs were also examined,
as well as global clinical efficacy and safety.
The evaluations were performed at baseline,
at 4 weeks and 4 months. Results were recorded
from medical charts of data collection.
The score of the CURS was based on the
evaluation of 13 items: 3 classic elements
(tremor, rigidity, bradykinesia) and 10 non-
motor symptoms or motor non-classical
symptoms (facial expression, seborrhea,
drooling, impaired speech, finger dexterity,
foot tapping, arising from chair, posture,
postural stability, gait disturbance). Severity
was assessed as: 0 (normal) to 4 (severe). An
enhancement in the CURS scale was defined as
a reduction in score of at least 1 point.
The UPDRS was calculated from the
sequence of four parts UPDRS complications
scale, which assesses the predictability, the
appearance, and the time spent in the ‘off’
phase.
QoL was examined using the PD-Q39, which
consists of 39 items that can be added together
to generate eight subscales, and a total score.
In this analysis, the summed scores could
range from 0 (no difficulty) to 100 (maximum
difficulty). At the final evaluation at 4 months,
investigators were asked to rate on a global level
the efficacy and tolerability of rasagiline as:
(a) very good, (b) good, (c) modest, or (d) poor.
In a post hoc analysis, the overall tolerability
assessment was also grouped by age (\70 years;
[70 years).
Results
The authors collected data on 754 patients. In
total, 545 patients were treated with rasagiline
as an adjunctive therapy and 209 patients
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received rasagiline as monotherapy. All patients
on adjunctive therapy and 44 patients on
monotherapy (21%) had received treatment
for PD in the 3 months preceding the study
period, most often DA and levodopa/dopa-
decarboxylase (DDI) preparations.
In total, 29 patients were switched from
treatment with rasagiline plus selegiline at the
beginning of the study, forming the subgroup
of ‘switch’ patients.
In addition to therapies for PD, medications
taken concurrently during the study included
beta-blockers (36% of patients), analgesics
(22%), antidepressants (SSRI excluded 14%),
and diuretics (13%). The average duration of
treatment with rasagiline was 118.2 (±33.7)
days for the total study population, 120.3
(±25.4) days for the monotherapy group, and
117.4 (±36.4) days for the combination therapy
group. During the study period, PD
combination therapy remained unchanged in
86.6% of patients. Only 73 patients (13.4%)
changed concomitant therapy, including 42
patients with an adjusted dose (mainly of
levodopa and DA), 24 patients with drugs then
suspended (especially DA), and 18 patients with
new prescriptions (mainly levodopa and DA). In
the subgroup of switch patients, the pre-
treatment doses of selegiline ranged from 1.25
to 20.0 mg/day, but were more frequently
5.0 mg/day (12/29 patients) or 10.0 mg/day (8/
29 patients). The duration of treatment with
selegiline and rasagiline consisted of a few days
(mostly 1–3 days) in the majority of patients
(23/29 patients).
Efficacy
Patients treated with rasagiline showed a
significant improvement in total CURS score
over a period of 4 months, both as
monotherapy (4.1-point improvement) and in
combination (4.6-point improvement) groups.
There was also a significant improvement from
baseline in the CURS classical PD motor
symptoms (sum of tremor, rigidity, and
bradykinesia scores single item) and in the
non-classical and classical motor symptoms.
All individual sub-items of the CURS were
improved (i.e., defined as a reduction in score
of at least 1 point) in more than 62% of patients
in the monotherapy group, and up to 48% of
patients receiving combination therapy at the
final assessment.
Modifications to the UPDRS
Fluctuations in the UPDRS clinical end point
were examined in 489 patients receiving
combination therapy, using the available
answers to at least one of four questions. Based
on this evaluation, the proportion of patients
without ‘off’ periods of wakefulness during the
day increased from 33% to 50% during the
4-month period of clinical observation. This
confirmed a significant difference in the amount
of ‘off’ time between the start and the end of the
study (P\0.001). Furthermore, between the
clinical examination at baseline and at the
final evaluation, the percentage of patients
with predictable periods of ‘off’ fell from 33%
(95% CI 28.8–37.2) to 24% (95% CI 20.2–27.8),
and the percentage of patients with
unpredictable ‘off’ periods fell from 43% (95%
CI 38.9–47.8) to 31% (95% CI 26.8–35.0), with
the confidence interval indicating a significant
difference in both cases (P\0.05). A significant
difference was also detected in the percentage of
patients who experienced sudden periods of ‘off’
(even a few seconds), which also fell from 30%
(95% CI 26.2–34.3) to 16% (95% CI 12.6–19.1)
during the study (P\0.05).
Periods of Time in Daily ‘Off’
The time period in daily ‘off’, as recorded in
patient diaries, was examined only in patients
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receiving combination therapy. The evaluation
of efficacy was based on data from the diaries of
203 patients who completed all three phases of
the study. During the study, considering a
median daily period of time equal to ‘off’
significantly decreased from 120 to 45 min
(P\0.001), with a significant reduction as
early as the mid-term (1–4 weeks).
Evaluation of Overall Effectiveness
At the final evaluation, the overall effectiveness
of treatment with rasagiline was assessed by the
investigators as good or very good in 133/199
patients on monotherapy (67%) and in 278/510
patients on combination therapy (55%). PDQ-
39 data were supplemented by QoL data
reported by patients in a subjective analysis.
The overall rating to the PDQ-39, and all eight
subscales of the PDQ-39, showed a significant
improvement from baseline to final assessment
with rasagiline as monotherapy or in
combination therapy (P\0.001). Most efficacy
was observed in the subscales of the PDQ-39:
‘stigma’ in the activities of daily life
(monotherapy), mobility, and emotional
feelings (combination therapy), although the
most significant improvements were noted in
subscales which value mobility and ADL
(monotherapy), and supporting social
interaction and communication (combination
therapy).
Safety and Tolerability
AEs/ADRs were reported by 5/209 monotherapy
patients (2%) and 46/545 patients in the
combined therapy group (8%). The ADR/AES
most commonly reported were: nausea,
dizziness, headache, and vomiting. A total of
100 patients (13.5%) were withdrawn from the
study prematurely [including 56 patients (7.6%)
who were withdrawn at the visit of the 4th
week].
The discontinuation rate was higher in the
combination therapy group compared with the
monotherapy group, both during the study [49
patients (9.1%) vs. 7 patients (3.4%)] and at the
final evaluation [87 patients (16.2%) vs. 13
patients (6.4%)]. The most common cause of
study discontinuation in both groups was lack
of efficacy [monotherapy: 7 patients (3.3%);
combination therapy: 31 patients (5.7%)].
Two patients on monotherapy (1%) and 27
patients receiving combination therapy (5%)
withdrew from the study due to lack of
tolerability. At the final evaluation, the overall
tolerability of treatment with rasagiline was
assessed by the investigators as good or very
good in 193/199 patients in the monotherapy
group (97%) and in 474/527 patients in the
combination therapy group (90%). The post
hoc analysis showed that the tolerability of
rasagiline (as monotherapy or in combination
therapy) did not seem to be influenced by age
and was evaluated as good or very good in
387/420 patients (92%) aged \70 years, and
276/302 patients (91%) aged C70 years.
Switch to Rasagiline Group
The subgroup of patients who switched to
rasagiline showed a significant improvement
in symptoms between baseline and the final
evaluation in both classical and non-classical
motor scores (CURS total score, P\0.001;
classical ? nonclassical motor score ? partial
non-motor score, P = 0.002), and in the
percentage of patients free from ‘off’ periods
during the day (36% vs. 48%, respectively). QoL
questionnaires showed that these patients had
also benefited from an improvement of 6.5
points in the PDQ-39 total score (P = 0.002) and
significant improvements in specific individual
PDQ-39 scores in motility (P = 0.01), ADL
(P\0.01), emotional score (P\0.05), and
‘stigma’ (P = 0.001). The tolerability to the
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drug in this subgroup of patients was assessed at
the final visit as good or very good in 25/26
patients (96%).
Summary
Monotherapy or combination therapy with
rasagiline was able to improve the symptoms
of PD, reduce the amount of ‘off’ time, improve
QoL, and also demonstrated a favorable
tolerability. Furthermore, rasagiline had a
simple dosing schedule of one tablet, once per
day, without titration. These results are
consistent with those obtained in clinical
studies (TEMPO, PRESTO, and LARGO).
Time to Onset of Anti-parkinsonian Effect
Wilson et al. [40] studied 272 PD patients to
assess the time to onset and magnitude of the
effects of rasagiline, either alone or as an
adjunct in an open-label study. Timing
evaluations were 1, 2, 4, and 12 weeks.
Patients were divided into two arms: rasagiline
1 mg/day monotherapy (n = 122) or add-on
rasagiline 0.5 mg (could be increased to 1 mg
at the opinion of the investigator; n = 147)
Main outcome measures were the evaluation of
the ‘bradykinesia score’ between baseline and
12 weeks of therapy, the CGI score, the Clinical
Global Evaluation-Severity of Illness (CGE-SI)
score, Schwab and England ADL score,
satisfaction/ease-of-use questionnaire (SAEQ)
and investigator for patient, and safety and
tolerability. Statistical analyses were conducted
according to the ITT principle and analysis of
covariance (ANCOVA).
Results
The magnitude of beneficial effect was similar
in monotherapy and adjunct therapy patients.
No significant dopaminergic side effects,
tyramine reactions, or interactions with
antidepressants were observed in the 12-week
trial.
Conclusion
Rasagiline has a measurable beneficial effect on
PD symptoms within 1 week of treatment.
Rasagiline has a similar magnitude of benefit
in monotherapy and adjunct therapy patients.
Adverse interactions between antidepressants
and rasagiline were not observed in patients in
this trial.
Rapid Efficacy of Rasagiline on Motor
Symptoms
Zambito Marsala et al. [41] studied 102 patients
(55 males and 47 females) who started
treatment with rasagiline as outpatients: 26
patients were PD therapy naı¨ve and 76
received rasagiline as add-on therapy (i.e.,
were already receiving levodopa and/or DA).
The mean (±SD) age was 70.4 ± 8.7 years
(median 71 years). The mean time from PD
diagnosis was 4.7 years. The mean UPDRS III
total score at baseline was comparable in the
two subgroups (23.2 and 22.1 in therapy-naı¨ve
and in add-on therapy patients, respectively;
P = 0.636). Treatment with rasagiline was
associated with statistically significant
decreases from baseline in mean UPDRS III
total score in the overall sample and in the
two subgroups (P\0.0001 at week 1 and week
4). The mean (±SD) change from baseline in the
overall sample was -6.7 ± 5.3 (95% CI -7.8 to
-5.7) at week 1, and -8.9 ± 6.1 (95% CI -10.1
to -7.7) at week 4. Changes from baseline were
-6.7 ± 4.4 (95% CI -8.4 to -4.9) at week 1 and
-8.8 ± 5.9 (95% CI -11.2 to -6.4) at week 4 in
therapy-naı¨ve patients, and -6.8 ± 5.6 (95% CI
-8.0 to -5.5) at week 1 and -9.0 ± 6.1 (95% CI
-10.4 to -7.6) at week 4 in add-on therapy
patients. Significant improvements from
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baseline to both week 1 and week 4 were
observed in the overall population for all of
the examined UPDRS III items (P\0.001). The
mean HY score at baseline was significantly
higher in the add-on therapy group than in the
therapy-naive subgroup (2.40 and 1.90,
respectively; P = 0.021). A significant decrease
in mean HY score from baseline to week 1 and
week 4 (P\0.0001 at any time) was observed in
the overall sample, as well as in therapy-naı¨ve
and in add-on therapy patients. The extent of
the improvement from baseline was more
marked in add-on therapy patients than in
therapy-naı¨ve patients. The mean (±SD)
change from baseline in the overall sample
was -0.40 ± 0.58 (95% CI -0.51 to -0.29) at
week 1 and -0.67 ± 0.61 (95% CI -0.81 to
-0.53) at week 4. Changes from baseline were
-0.23 ± 0.32 (95% CI -0.36.4 to -0.10) at week
1 and -0.46 ± 0.48 (95% CI -0.66 to -0.26)
at week 4 in therapy-naı¨ve patients, and
-0.46 ± 0.64 (95% CI -0.60 to -0.31) at week
1 and -0.74 ± 0.76 (95% CI -0.91 to -0.57) at
week 4 in add-on therapy patients.
In the analysis by age, based on median
value (B or[71 years), the mean UPDRS III total
score at baseline was significantly higher in
patients aged [71 years than in the younger
cohort (25.9 and 19.0, respectively; P = 0.001).
The mean UPDRS III total score significantly
decreased from baseline to both week 1 and
week 4 in both subgroups (P\0.0001): the
mean decrease from baseline was slightly
higher in older patients than in the younger
cohort (-7.7 ± 6.2 vs. -5.8 ± 3.2 at Week, and
-10.0 ± 7.0 vs. -7.9 ± 4.8 at week 4). However,
the difference between subgroups in percentage
change from baseline was not statistically
significant at both week 1 (mean difference
-2.6%; 95% CI -9.4 to 4.1; P = 0.440) and week
4 (mean difference -4.5; 95% CI -12.5 to 3.4;
P = 0.261). As for UPDRS III total score, the
mean HY score at baseline was significantly
higher in the older than in the younger cohort
(2.61 and 1.96, respectively; P\0.001).
Significant decreases from baseline in mean
HY score were observed in the two subgroups
by median age (P\0.0001), with more marked
decreases in older than in younger patients
(-0.52 ± 0.68 vs. -0.28 ± 0.45 at week 1. and
-0.83 ± 0.79 vs. -0.52 ± 0.60 at week 4). There
were no statistically significant differences
between subgroups at week 1 (mean difference
7.1%; 95% CI -1.0 to 12.5; P = 0.085) or week 4
(mean difference 6.8%; 95% CI -2.1 to 15.8;
P = 0.134) in percentage changes from baseline.
In the analysis by gender, the mean decrease
from baseline in total UPDRS III score was
comparable in males (-6.4 ± 4.6 at week 1 and
-9.0 ± 5.9 at week 4) and females (-7.1 ± 6.1 at
week 1 and -8.9 ± 6.3 at week 4), while the
mean decrease from baseline in mean HY score
was slightly higher in females (-0.47 ± 0.75 at
week 1 and -0.71 ± 0.79 at week 4) than in
males (-0.34 ± 0.38 at week 1 and -0.63 ± 0.64
at week 4). If we evaluate patients who showed a
benefit [20% on the UPDRS III, we notice that
patients showed an average improvement equal
to 30.6% (comparing week 1 with baseline)
mean (SD) = -30.64 (17.120) and 41.7%
(comparing week 1 with baseline) mean
(SD) = -30.64 (17.120). Considering patients
aged [71 years (n = 50), 44 (88.0%) were
classed as responders versus 6 (12.0%) non-
responders. In the group of patients aged
B71 years (n = 52), 42 (80.8%) were responders
versus 10 (19.2%) non-responders (Chi-square
P value = 0.315).
Pharmacoeconomic Study of Rasagiline
Hudry et al. [42] conducted a study to evaluate
the cost-benefit of rasagiline and entacapone as
adjunctive therapy to levodopa compared with
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levodopa alone in patients with PD and motor
fluctuations in Finland. The primary analysis
was performed according to the social
costs as recommended by International
Pharmacoeconomic Finns, taking into account
both the direct and the indirect costs. It was also
performed in a secondary analysis taking into
account only the direct costs [43].
Model Pharmacoeconomics
The study used a Markov model adapted from a
model developed originally by Nuijten [44] and
adapted from Palmer [45]. The Markov model
was chosen because it allows modeling the
long-term evolution of chronic diseases
classifying patients into a finite number of
states (clinical conditions). This model made it
possible to simulate the progression of patients
through three different clinical conditions. Two
of the three clinical conditions had to meet the
criteria in which patients spent a percentage of
time during ‘off’ each day, either 25% or less
off-time/day or greater than 25% off-time/day.
The third condition was that of patients
reported as ‘dead’. The threshold cutoff of 25%
was obtained from a study that showed that the
onset of motor fluctuations determines a
parallel increase in costs.
In this study, we adopted the structure of
the health states of the model of Palmer and
chose a time limit of 2 years. The study
duration was reduced because it reflects only a
limited period in the natural history of the
disease, and factors such as the UPDRS and HY
scale, autonomic dysfunction, gait disturbance,
cognitive impairment, and concomitant or
subsequent disease progression have not been
taken into account in the model. The extension
of the model beyond 2 years could have
resulted in poor validity that does not
accurately reflect clinical practice. Moreover,
the therapeutic management of PD motor
fluctuations is difficult to standardize, because
the prevalence of comorbidity increases with
the progression of the disease. Also, 15–40% of
patients with PD present with psychiatric
complications that require additional
medications, resulting in admission to a
nursing home and therefore higher costs. The
model has been limited to a period of time
during which the comparison between
different strategies of anti-parkinsonian drugs
was realistic. The Markov cycle length was
4 months, which would reflect the normal
management of PD in Finland, where patients
are examined by a doctor about three times a
year. Unlike the Palmer model, this model
included all PD patients with motor
fluctuations if they had started the cycle 1, to
reflect more accurately the target populations
defined for rasagiline treatment. Clinical and
economic pharmacoeconomic analyses were
conducted using the Data TreeAge software,
version 4.0 (Tree Age Software, Williamstown,
MA). The LARGO trial was a 4-month,
multicenter, double-blind, randomized,
placebo- and entacapone-controlled, parallel-
group study designed to compare the efficacy,
tolerability, and safety of rasagiline versus
placebo in patients with treated PD with
motor fluctuations. Its design and results have
been described elsewhere.
Basic Analysis
The results and average costs and their SD were
calculated according to a stochastic approach
(Monte Carlo simulation with 10,000 iterations)
with prior distributions to take account of the
variability in each parameter [46]. The
distribution of the results was drawn up on
the basis of 10,000 iterations. The incremental
cost-effectiveness ratio (ICER) was calculated in
the absence of dominance (i.e., better efficiency
and less cost).
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Sensitivity Analysis
The multivariate probabilistic approach used in
this study took into account the uncertainty
related to all variables. The best and worst case
scenarios were used to test the hypothesis of
effectiveness in the standard care group. In the
best of cases, patients in the standard care arm
could not improve their daily ‘off’ time in cycle
1 or any additional cycles. At worst, patients in
the standard care arm could improve their daily
‘off’ time in cycles 1–3, just as for patients in the
active treatment arm. This approach was the
most prudent for treatment with rasagiline from
a methodological point of view, but less likely
from a clinical point of view. Another
sensitivity analysis was to vary the price of
rasagiline through a decrease or an increase in
percentage of the price of entacapone to assess
the impact of a price difference between the two
drugs on cost-effectiveness.
Results
During the evaluation period of 2 years,
rasagiline has dominated standard care from a
social point of view. Rasagiline has
demonstrated an association with a 0.13 more
per quality-adjusted life years (QALYs) and in
over 55% of the time spent in the most with
25% or less of off-time/day compared to
standard treatment. The increase in total
effectiveness was not insignificant, with cost
savings of €930 per treated patient, but this did
not reach statistical significance. If we consider
only the direct costs of rasagiline, there was an
increase in direct costs of €2130 compared with
standard care. ICERs were €17,800 per
additional QALY gained and €430 per
additional month spent with 25% or less off-
time per day.
During the evaluation period of 2 years from
a social point of view, entacapone obtained a
better response compared with standard care.
Treatment with entacapone was associated with
a 0.12 additional QALYs and 55% more time
spent with 25% or less of the period in ‘off’
compared with standard treatment. In total, the
cost saving was estimated at €830 per patient
treated. Considering the prospect of direct
costs, the ICER was €18,600 for additional
QALYs acquired and €450 per additional
month spent with 25% or less of the day ‘off’.
Both rasagiline and entacapone proved
better than the standard treatment when
taking into account both direct and indirect
costs. The drug costs associated with rasagiline
or entacapone represent a significant
proportion of the total (16%) and direct (30%)
costs.
Indirect costs account for about half of total
costs for all treatment strategies considering
that PD is a cause of early retirement in more
than 60% of cases. The results in the best cases
have shown that the increase of effectiveness of
rasagiline compared to the norm has reached
0.18 QALYs (14% increase) and 7.25 months in
the time spent with 25% or less of ‘off’/day (an
increase of 56%). The total saving is €2,900 per
patient. Incremental direct costs of rasagiline
versus standard care were reduced to €1,400 per
patient. Similar results were obtained for the
comparison of entacapone and standard care. In
the best case, both rasagiline and entacapone
were the better strategies than standard
treatment from a social point of view. In the
worst case, the incremental effectiveness of
rasagiline compared with standard treatment
was 0.06 QALYs and 2.6 additional months
spent with 25% or less of ‘off’-time/day in favor
of rasagiline. In this scenario, rasagiline had
€3,100 and €1,550 additional direct and total
costs, respectively, compared with standard
treatment. Even on pairing the costs in both
clinical conditions (i.e., 1:1 ratio), neither
rasagiline nor entacapone had better results
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over the other, as they were more effective but
also more expensive compared with standard
therapy (additional costs of €2,000). Decreasing
the price of rasagiline by 20% compared to the
price of entacapone has resulted in a cost saving
from €930 to €1,500 per patient over 2 years
compared with standard care. The price increase
of 10% compared with entacapone also showed
a cost saving of €300 compared with standard
treatment.
Conclusions
Treatment with rasagiline was convenient and
cost saving compared with standard treatment
alone and compared with levodopa alone from
a social point of view. It was not surprising that
rasagiline and entacapone achieved similar
performance compared with standard care
when considering a similar price for both
treatments. Rasagiline is an alternative option
for the treatment of advanced PD where unmet
needs remain very high.
DISCUSSION
The main clinical support for the use of
rasagiline arises from three large-scale studies,
investigating rasagiline as monotherapy in
patients with early PD (TEMPO) and as adjunct
therapy (to levodopa) in patients with moderate
to advanced PD (PRESTO and LARGO).
In the 6-month, placebo-controlled TEMPO
study, rasagiline significantly improved PD
symptoms (including specific measures of
motor function, ADL, tremor, and
bradykinesia), and positively affected overall
illness severity and patient QoL [11]. The
subsequent 6-month active treatment phase of
this study indicated that early use of rasagiline
may be able to delay symptom progression [35],
with the beneficial effect of early treatment
maintained for up to 6.5 years in the open-label
study extension [36]. Data obtained from the
ADAGIO study showed similar results relating
to delayed symptom progression [34, 47].
Rasagiline also significantly improved cardinal
motor symptoms, in patients with more
advanced disease, and reduced daily ‘off’ time
by up to 0.94 h/day versus placebo in patients
experiencing motor fluctuations [23, 24]. In all
three pivotal clinical studies, rasagiline was well
tolerated and was not associated with any
specific safety concerns [11, 23, 24].
Specifically in the TEMPO study, the change
in total UPDRS score between baseline and the
week 26 visit showed significant differences
between active treatment and placebo. In
addition, a higher proportion of patients in
the active treatment groups responded to
therapy, as judged by their change in total
UPDRS score compared with the placebo group.
From the analysis of the PRESTO study, it
could be demonstrated that between baseline
and the visit at 26 weeks, rasagiline treatment
was well tolerated and was associated with
several therapeutic benefits in PD patients
with motor fluctuations, despite optimized
levodopa, including decreased ‘off’ time on
home diaries completed by patients, and
improvement in CGI performed by blinded
examiners. Neurologic function improved
during ‘off’ times (ADL scores based on patient
reports) and during ‘on’ times (overall motor,
postural instability and gait, rigidity,
bradykinesia, and tremor scores based on
patient reports and direct examination). These
benefits were measurable at the first efficacy
assessment 6 weeks after starting treatment and
were sustained throughout the treatment
period. Benefits tended to be greater in
patients treated with 1 mg/day rasagiline
compared with 0.5 mg/day, but differences
between the two rasagiline dosages were not
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significant for most end points. Observed
decreases in daily ‘off’ time were associated
with nearly equal increases in ‘on’ time.
The results of LARGO trial showed that 1 mg/
day rasagiline without titration reduced ‘off’
time and improved motor symptom control in
patients with PD who were on optimum
treatment of levodopa, DA, and other anti-
parkinsonian therapies, and the effects were
achieved with a good safety profile. Rasagiline
reduced daily ‘off’ time by about 20% daily.
Notably, this beneficial effect was independent
of age, adjunct use of DA, and adjustments of
levodopa dose. The beneficial effect of rasagiline
during ‘off’ time was accompanied by a
corresponding increase in ‘on’ time without
troublesome dyskinesia, whereas the duration
of ‘on’ time with troublesome dyskinesia did not
change. The clinical relevance of the primary
outcome was supported by the CGI measure.
Rasagiline provided a significant
improvement in UPDRS-PIGD and UPDRS-
freezing scores. These scores, although not
fully validated, relate to symptoms such as
postural instability and gait problems, which
are regarded as poorly responsive to
dopaminergic mechanisms and represent
another unmet need of treatment for PD [48].
Rasagiline achieved the two main goals of
adjunct therapy for PD, reducing disability and
decreasing fluctuations. Rasagiline effectively
reduced the time spent in the ‘off’ state and
increased ‘on’ time without raising the
frequency of troublesome dyskinesia.
The results of the ADAGIO study [34] showed
that the group of patients treated early with
1 mg/day rasagiline reached the three clinical
end points set. Only two of the end points were
achieved with the 2 mg/day dose. It can be
deduced from the ADAGIO study that early
treatment with rasagiline 1 mg/day guarantees
benefits that are not are obtained with delayed
treatment, despite the use of the same drug.
These results are consistent with the possibility
that rasagiline may have 1 mg/day slowing
effects in PD. In post hoc analyses, patients
with baseline UPDRS scores in the highest
quartile who received either 1 or 2 mg/day
rasagiline met all three primary end points. In
the subgroup with UPDRS scores in the highest
quartile who received rasagiline at a dose of
2 mg/day, patients in the early-start group had
less worsening in UPDRS scores from baseline to
week 72 than those in the delayed-start group
(-3.63 ± 1.72 points, P = 0.04).
In patients with UPDRS scores in the highest
quartile at baseline who received rasagiline at a
dose of 1 mg/day, those in the early-start group
had less worsening in the total UPDRS score from
baseline to week 72 than patients in the delayed-
start group (-3.40 ± 1.66 points, P = 0.04).
Patients enrolled in the TEMPO study were
evaluated in a further trial to test the long-term
efficacy, safety, and tolerability of rasagiline in
all patients who received rasagiline as
monotherapy during the trial and subsequent
open-label extension [49]. The cohort of
patients who were treated with rasagiline
monotherapy for 2 years was older, with lower
UPDRS scores on study entry, than those
requiring adjunctive dopaminergics in the
same time frame. The sequence of starting with
rasagiline and adding a DA before turning to
levodopa was the most commonly chosen
approach to long-term therapy. The high
proportion of patients maintained on
rasagiline monotherapy in the first 2 years of
this trial (46%) suggests that initiating rasagiline
therapy in early PD patients offers an efficacious
and safe alternative strategy for the use of other
dopaminergic treatments for a period of time.
The study by Hauser et al. [35] compared the
long-term outcome in patients with early-stage
PD in the TEMPO study treated with rasagiline
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earlier in life with those treated late in PD.
During the extension phase of the study
reported here, patients continued to receive
rasagiline, and other PD medications could be
added and adjusted as necessary. For the entire
follow-up period of 6.5 years, the mean
difference in change from baseline in total
UPDRS scores between early- and delayed-start
patients was 2.5 units, corresponding to a mean
relative difference of 16%. Similarly, for patients
who continued in the study up to database lock,
the adjusted mean difference in change in total
UPDRS scores was 2.4 units, corresponding to a
mean relative difference of 17% in favor of the
early-start rasagiline group. This suggests that
early treatment with rasagiline may offer
clinical benefits compared to a delay of
treatment for 6 months, and these benefits
may be enduring and apparent even as
patients are treated with other PD medications.
The post-marketing observational study
presented investigated the efficacy and
tolerability of rasagiline (as monotherapy or in
combination therapy) in daily clinical practice
[37]. Either as monotherapy or in combination
therapy, rasagiline improved symptoms of PD,
reduced the ‘off’ time, and improved severities
of the classical motor symptoms of PD in
42–62% of patients, which is a clinically
meaningful outcome. The severities of non-
classic motor/non-motor symptoms including
speech disorder, finger dexterity, and postural
stability were improved in 31–58% of patients,
with favorable tolerability. These results are
consistent with the TEMPO, PRESTO and
LARGO studies.
Finally, the cost-utility model of rasagiline in
advanced PD [42] demonstrated clinical benefits
of rasagiline over standard treatment associated
with an increased time spent with little or no
motor fluctuations and an increase in QALYs.
Sensitivity analyses showed a greater clinical
benefit with rasagiline than with standard
treatment. From a social point of view after
2 years, rasagiline as adjunctive therapy to
levodopa showed greater efficiency compared
with levodopa alone, without additional costs.
From the social point of view, rasagiline
demonstrated a reduced utilization of health-
care resources as well as a reduction of indirect
costs and, therefore, potential cost savings. The
results of this study support the use of rasagiline
as an alternative to levodopa in patients with
PD and motor fluctuations. Even with a
different mechanism of action, rasagiline was
an alternative therapeutic agent to entacapone
at no additional cost to the community.
Neuroprotective Effects
Preclinical studies [49, 50] have shown that
MAO-B inhibitors can protect neurons from
oxidative stress, apoptosis, and other forms of
injury in multiple experimental models. The
possibility that rasagiline might have a
neuroprotective effect is supported by
laboratory studies showing that the drug and
its metabolite 1-(R)-aminoindan have anti-
apoptotic effects and protect neurons from a
variety of toxins in various models [51–54].
Neuroprotection in these models appears to be
related to a propargyl ring incorporated within
the rasagiline molecule rather than to MAO-B
inhibition [54, 55]. In multiple cell culture and
animal models, rasagiline has a proven
neuroprotective effect [56–58]. Rasagiline
reduces neuronal loss in animal models of N-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) administration [59], oxidative stress
[60], hypoxic injury [53], cerebral trauma [61],
and amyotrophic lateral sclerosis (ALS) [56]. The
MAO-inhibition its propargylamine moiety
protects mitochondrial viability and the
mitochondrial permeability transition pore by
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activating Bcl-2 and protein kinase C, and
downregulating pro-apoptotic FAS and Bax
[54, 55]. Rasagiline also increases nerve growth
factor, glial cell-derived neurotrophic factor,
and brain-derived neurotrophic factor [62].
The most likely mechanism of action of
rasagiline is through inhibition of MAO-B
leading to slower catabolism of endogenous
dopamine. However, other mechanisms are
also possible. In addition to the effect of MAO-
B on dopamine catabolism, rasagiline possesses
an aminoindan metabolite with anti-
parkinsonian properties [63]. Rasagiline has
been shown to protect neurons against a range
of experimentally induced neuronal injuries [59,
64] in animal models and exert an anti-
apoptotic effect in cell culture [60]. Another
possible mechanism of action of rasagiline is
through slowing the rate of loss of dopaminergic
neurons. Therefore, the long-term benefit
observed with early initiation of rasagiline
could be due to a neuroprotective effect.
Cognition Effects
The primary effect of rasagiline is to improve
the efficiency of dopaminergic transmission,
specifically dopaminergic function in the
prefrontal cortex, which is known to be
depleted of dopamine early in cognitive
impairment, but not in demented patients
with PD [65]. Several studies have shown that
the MAO-B inhibitor selegiline provides some
beneficial effects on cognition and may confer
beneficial effects on certain aspects of attention
and executive functions in non-demented PD
patients with cognitive impairment [66, 67].
Recent studies have also confirmed the effects of
rasagiline on cognitive function in cognitively
impaired, but not demented patients with PD,
suggesting that rasagiline may confer beneficial
effects on certain aspects of attention and
executive functions in non-demented PD
patients with cognitive impairment [68].
CONCLUSION
Rasagiline has shown strong evidence of
effectiveness on parkinsonian motor symptoms,
good tolerability and ease of use in patients, as
monotherapy or as adjunctive therapy. These add
to the effects on cognition and to the possible
neuroprotective activity of rasagiline. The motor
effectiveness produced by rasagiline has been
demonstrated in many studies, with durable
response, with additional studies showing rapid
onset of action. Considering also the simplicity of
administration, good compliance, and the low
side effects, the importance of rasagiline in the
treatment of patients with PD at all stages of the
disease is well established.
ACKNOWLEDGMENTS
Dr. Sandro Zambito Marsala is the guarantor for
this article and takes responsibility for the
integrity of the work as a whole. No funding
or sponsorship was received for this study or
publication of this article. This work is the result
of data collected by all the authors; the final
work was written by Dr. Pistacchi and Dr.
Sandro Zambito Marsala.
Conflict of interest. Michele Pistacchi,
Francesco Martinello, Manuela Gioulis, and
Sandro Zambito Marsala declare no conflict of
interest.
Compliance with ethical guidelines. The
analysis in this article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Neurol Ther (2014) 3:41–66 63
123
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Le Witt PA. Levodopa for the treatment of
Parkinson’s disease. N Engl J Med. 2008;359:2468–
76.
2. Lees A. Alternatives to levodopa in the initial
treatment of early Parkinson’s disease. Drugs
Aging. 2005;22:731–40.
3. Elmer LW, Bertoni JM. The increasing role of
monoamine oxidase type B inhibitors in
Parkinson’s disease therapy. Expert Opin
Pharmacother. 2008;9:2759–72.
4. Hauser RA, Zesiewicz TA. Advances in the
pharmacologic management of early Parkinson
disease. Neurologist. 2007;13:126–32.
5. Jenner P, Langston JW. Explaining ADAGIO: a
critical review of the biological basis for the
clinical effects of rasagiline. Mov Disord.
2011;26:2316–23.
6. Oldfield V, Keating GM, Perry CM. Rasagiline: a
review of its use in the management of Parkinson’s
disease. Drugs. 2007;67:1725–47.
7. Youdim MB, Gross A, Finberg JP. Rasagiline [N-
propargyl-1R(?)-aminoindan], a selective and
potent inhibitor of mitochondrial monoamine
oxidase B. Br J Pharmacol. 2001;132:500–6.
8. The´bault JJ, Guillaume M, Levy R. Tolerability,
safety, pharmacodynamics, and pharmacokinetics
of rasagiline: a potent, selective, and irreversible
monoamine oxidase type B inhibitor.
Pharmacotherapy. 2004;24:1295–305.
9. Rabey JM, Sagi I, Huberman M, et al. Rasagiline
mesylate, a new MAO-B inhibitor for the treatment
of Parkinson’s disease: a double-blind study as
adjunctive therapy to levodopa. Clin
Neuropharmacol. 2000;23:324–30.
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA
statement for reporting systematic reviews and
meta-analyses of studies that evaluate health care
interventions: explanation and elaboration. PLoS
Med. 2009;6:e1000100.
11. Parkinson Study Group. A controlled trial of
rasagiline in early Parkinson disease: the TEMPO
study. Arch Neurol. 2002;59:1937–43.
12. Fahn S, Elton RL, Members of the UPDRS
Development Committee. Unified Parkinson’s
disease rating scale. In: Fahn S, Marsden CD,
Calne DB, Lieberman A, editors. Recent
developments in Parkinson’s disease. Florham
Park: MacMillan Health Care Information; 1987.
p. 153–63.
13. Katz S, Ford AB, Moskowitz RW, Jackson BA,
Jaffe MW. Studies of illness in the aged. The
index of ADL: a standardized measure of
biological and psychosocial function. JAMA.
1963;185:914–9.
14. Lawton MP, Brody EM. Assessment of older people:
self-maintaining and instrumental activities of
daily living. Gerontologist. 1969;9:179–86.
15. McDermott MP, Jankovic J, Carter J, et al. Factors
predictive of the need for levodopa therapy in early,
untreated Parkinson’s disease. The Parkinson Study
Group. Arch Neurol. 1995;52:565–70.
16. Hoehn MM, Yahr MD. Parkinsonism: onset,
progression and mortality. Neurology.
1967;17:427–42.
17. Schwab RS, England AC Jr. Projection technique for
evaluating surgery in Parkinson’s disease. In:
Gillingham FJ, Donaldson IML, editors. Third
symposium on Parkinson’s disease, held at the
Royal College of Surgeons of Edinburgh on 20, 21
and 22 May 1968. Edinburgh: E & S Livingstone;
1969. p. 152–7.
18. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh
J. An inventory for measuring depression. Arch Gen
Psychiatry. 1961;4:561–71.
19. Folstein MF, Folstein SE, McHugh PR. ‘‘Mini-Mental
State’’. A practical method for grading the cognitive
state of patients for the clinician. J Psychiatr Res.
1975;12:189–98.
20. Langston JW, Widner H, Goetz CG, et al. Core
assessment program for intracerebral
transplantations (CAPIT). Mov Disord. 1992;7:2–13.
21. Welsh M, McDermott MP, Holloway RG, et al.
Development and testing of the Parkinson’s disease
quality of life scale. Mov Disord. 2003;18:637–45.
22. Hochberg Y. A sharper Bonferroni procedure for
multiple tests of significance. Biometrika.
1988;75:800–2.
23. Parkinson Study Group. A randomized placebo-
controlled trial of rasagiline in levodopa-treated
64 Neurol Ther (2014) 3:41–66
123
patients with Parkinson disease and motor
fluctuations: the PRESTO study. Arch Neurol.
2005;62:241–8.
24. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as
an adjunct to levodopa in patients with Parkinson’s
disease and motor fluctuations (LARGO, Lasting
effect in Adjunct therapy with Rasagiline Given
Once daily, study): a randomised, double-blind,
parallel-group trial. Lancet. 2005;365:947–54.
25. Movement Disorder Society Task Force.
Management of Parkinson’s disease: an evidence-
based review. Mov Disord. 2002;17(Suppl.
4):S1–166.
26. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C.
Treatment interventions for Parkinson’s disease: an
evidence based assessment. Lancet. 2002;359:1589–
98.
27. Parkinson Study Group. Entacapone improves
motor fluctuations in levodopa-treated Parkinson’s
disease patients. Ann Neurol. 1997;42:747–55.
28. Rinne UK, Larsen JP, Siden A, Worm-Petersen J.
Entacapone enhances the response to levodopa in
parkinsonian patients with motor fluctuations.
Nomecomt Study Group. Neurology.
1998;51:1309–14.
29. National Institute for Mental Health. 028 CGI.
Clinical global impressions. In: Guy W, editor.
ECDEU assessment manual for
psychopharmacology. Rockville: US Department
of Health, Education, and Welfare; 1976. p. 217–22.
30. Elmer LW. Rasagiline adjunct therapy in patients
with Parkinson’s disease: post hoc analyses of the
PRESTO and LARGO trials. Parkinsonism Relat
Disord. 2013;19:930–6.
31. Schwid SR; for The PRESTO and LARGO
Investigators. Once-daily rasagiline produces
consistent treatment benefits in US and European
studies of Parkinson’s disease patients. Eur J Neurol.
2006;13:95 (abstract).
32. Poewe W for the PRESTO and LARGO Investigators.
Rasagiline provides significant benefits as adjunct
therapy in patients with moderate Parkinson’s
disease: subgroup analyses. 10th Congress of the
European Federation of Neurological Societies (EFNS)
2006, September 2–5, Glasgow, p. 1193 (Abstract).
33. Elmer LW for the PRESTO and LARGO
Investigators. Adjunctive rasagiline provides
significant benefits in all cardinal symptoms in
patients with moderate to advanced Parkinson’s
disease. 12th International Congress of Parkinson’s
Disease and Movement Disorders, 2008, June
22–26, Chicago, p. 666 (Abstract).
34. Olanow CW, Rascol O, Hauser R, et al. A double-
blind, delayed-start trial of rasagiline in Parkinson’s
disease. N Engl J Med. 2009;361:1268–78.
35. Hauser RA, Lew MF, Hurtig HI, et al. Long-term
outcome of early versus delayed rasagiline
treatment in early Parkinson’s disease. Mov
Disord. 2009;24:564–73.
36. Lew MF, Hauser RA, Hurtig HI, et al. Long-term
efficacy of rasagiline in early Parkinson’s disease.
Int J Neurosci. 2010;120:404–8.
37. Reichmann H, Jost WH. Efficacy and tolerability of
rasagiline in daily clinical use–a post-marketing
observational study in patients with Parkinson’s
disease. Eur J Neurol. 2010;17:1164–71.
38. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE,
Hoehn MM. Treatment of parkinsonism with
levodopa. Arch Neurol. 1969;21:343–54.
39. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R,
Hyman N. The Parkinson’s Disease Questionnaire
(PDQ-39): development and validation of a
Parkinson’s disease summary index score. Age
Ageing. 1997;26:353–7.
40. Wilson RE, Seeberger LC, Silver D, et al. Rasagiline:
time to onset of antiparkinson effect is similar
when used as a monotherapy or adjunct treatment.
Neurologist. 2011;17:318–24.
41. Zambito Marsala S, Vitaliani R, Volpe D, et al. Rapid
onset of efficacy of rasagiline in early Parkinson’s
disease. Neurol Sci. 2013;34:2007–13.
42. Hudry J, Rinne JO, Kera¨nen T, Eckert L, Cochran
JM. Cost-utility model of rasagiline in the
treatment of advanced Parkinson’s disease in
Finland. Ann Pharmacother. 2006;40:651–7.
43. Finnish Ministry of Social Affairs and Health.
Pharmaceutical pricing board. http://www.stm.fi/
en/social_and_health_services/pharmacotherapy.
Accessed 4 Dec 2004.
44. Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ,
Snyder E. Cost-effectiveness analysis of entacapone
in Parkinson’s disease: a Markov process analysis.
Value Health. 2001;4:316–28.
45. Palmer CS, Nuijten MJ, Schmier JK, Subedi P,
Snyder EH. Cost effectiveness of treatment of
Parkinson’s disease with entacapone in the United
States. Pharmacoeconomics. 2002;20:617–28.
46. Briggs AH, Ades AE, Price MJ. Probabilistic
sensitivity analysis for decision trees with multiple
branches: use of the Dirichlet distribution in a
Bayesian framework. Med Decis Making.
2003;23:341–50.
Neurol Ther (2014) 3:41–66 65
123
47. Olanow CW, Rascol O. Early rasagiline treatment
slows UPDRS decline in the ADAGIO delayed start
study. Ann Neurol. 2008;64(Suppl. 12):S68.
48. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-
Courbon C, Montastruc JL. Limitations of current
Parkinson’s disease therapy. Ann Neurol.
2003;53(Suppl. 3):S3–15.
49. Gotz ME, Breithaupt W, Sautter J, et al. Chronic
TVP-1012 (rasagiline) dose–activity response of
monoamine oxidases A and B in the brain of the
common marmoset. J Neural Transm Suppl.
1998;52:271–8.
50. Finberg JP, Takeshima T, Johnston JM, Commissiong
JW. Increased survival of dopaminergic neurons by
rasagiline, a monoamine oxidase B inhibitor.
NeuroReport. 1998;9:703–7.
51. Bar-Am O, Amit T, Youdim MB. Aminoindan and
hydroxyaminoindan, metabolites of rasagiline and
ladostigil, respectively, exert neuroprotective
properties in vitro. J Neurochem. 2007;103:500–8.
52. Stefanova N, Poewe W, Wenning GK. Rasagiline is
neuroprotective in a transgenic model of multiple
system atrophy. Exp Neurol. 2008;210:421–7.
53. Mandel S, Weinreb O, Amit T, Youdim MB.
Mechanism of neuroprotective action of the anti-
Parkinson drug rasagiline and its derivatives. Brain
Res Brain Res Rev. 2005;48:379–87.
54. Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O,
Youdim MB. Novel neuroprotective mechanism of
action of rasagiline is associated with its propargyl
moiety: interaction of Bcl-2 family members with
PKC pathway. Ann N Y Acad Sci.
2005;1053:348–55.
55. Youdim MB, Wadia A, Tatton W, Weinstock M. The
anti-Parkinson drug rasagiline and its
cholinesterase inhibitor derivatives exert
neuroprotection unrelated to MAO inhibition in
cell culture and in vivo. Ann N Y Acad Sci.
2001;939:450–8.
56. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph
AC. Rasagiline alone and in combination with
riluzole prolongs survival in an ALS mouse model.
J Neurol. 2004;251:1080–4.
57. Youdim MB, Bar Am O, Yogev-Falach M, et al.
Rasagiline: neurodegeneration, neuroprotection,
and mitochondrial permeability transition.
J Neurosci Res. 2005;79:172–9.
58. Maruyama W, Akao Y, Carrillo MC, Kitani K,
Youdium MB, Naoi M. Neuroprotection by
propargylamines in Parkinson’s disease:
suppression of apoptosis and induction of
prosurvival genes. Neurotoxicol Teratol.
2002;24:675–82.
59. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB.
Prevention of MPTP-induced neurotoxicity by
AGN-1133 and AGN-1135, selective inhibitors of
monoamine oxidase-B. Eur J Pharmacol.
1985;116:313–7.
60. Maruyama W, Yamamoto T, Kitani K, Carrillo MC,
Youdim M, Naoi M. Mechanism underlying anti-
apoptotic activity of a (–)deprenyl-related
propargylamine, rasagiline. Mech Ageing Dev.
2000;116:181–91.
61. Huang W, Chen Y, Shohami E, Weinstock M.
Neuroprotective effect of rasagiline, a selective
monoamine oxidase-B inhibitor, against closed
head injury in the mouse. Eur J Pharmacol.
1999;366:127–35.
62. Youdim MB, Maruyama W, Naoi M.
Neuropharmacological, neuroprotective and
amyloid precursor processing properties of
selective MAO-B inhibitor antiparkinsonian drug,
rasagiline. Drugs Today (Barc). 2005;41:369–91.
63. Finberg JP, Wang J, Bankiewikz K, Harvey-White J,
Kopin IJ, Goldstein DS. Increased striatal dopamine
production from L-DOPA following selective
inhibition of monoamine oxidase B by R(?)-N-
propargyl-1-aminoindan (rasagiline) in the
monkey. Neural Transm Suppl. 1998;52:279–85.
64. Abu-Raya S, Blaugrund E, Trembovler V,
Shilderman-Bloch E, Shohami E, Lazarovici P.
Rasagiline, a monoamine oxidase-B inhibitor,
protects NGF-differentiated PC12 cells against
oxygen–glucose deprivation. J Neurosci Res.
1999;58:456–63.
65. Elmer L, Schwid S, Eberly S, et al. Rasagiline-
associated motor improvement in PD occurs
without worsening of cognitive and behavioral
symptoms. J Neurol Sci. 2006;248:78–83.
66. Bortolato M, Chen K, Shih JC. Monoamine oxidase
inactivation: from pathophysiology to
therapeutics. Adv Drug Deliv Rev. 2008;60:1527–
33.
67. Lees AJ. Selegiline hydrochloride and cognition.
Acta Neurol Scand Suppl. 1991;136:91–4.
68. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects
of rasagiline on cognitive deficits in Parkinson’s
disease patients without dementia: a randomized,
double-blind, placebo-controlled, multicenter
study. Mov Disord. 2011;26:1851–8.
66 Neurol Ther (2014) 3:41–66
123
